Global Initiative for Chronic Obstructive Lung Disease classification of COPD, with recommended therapy
| Exacerbations | mMRC 0–1; CAT < 10 | mMRC ≥ 2; CAT ≥ 10 |
|---|---|---|
| 0 or 1 moderate exacerbation in the past year (not leading to hospital admission) | Group A Short- or long-acting bronchodilator | Group B LABA or LAMA |
| ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization within the past year | Group C LAMA | Group D LAMA or LAMA + LABA or inhaled corticosteroid + LABA |
CAT = COPD Assessment Test; COPD = chronic obstructive pulmonary disease; LABA = long-acting beta-2 agonist; LAMA = long-acting muscarinic receptor antagonist; mMRC = Modified Medical Research Council dyspnea questionnaire
Adapted from Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019. Accessed February 10, 2021. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf